Article de Fierce: AAIC: Biogen bolsters hopes for Alzheimer’s pivotal push as anti-tau oligo slows cognitive decline
Publié par Fierce le 14 juillet, 2026 : https://www.fiercebiotech.com/biotech/aaic-biogen-bolsters-hopes-pivotal-push-anti-tau-oligo-slows-cognitive-decline
Auteur: Darren Incorvaia
Aperçu de l’article
En anglais seulement
Biogen’s leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
In a closely watched presentation at the Alzheimer’s Association International Conference in London, Biogen shared results from the phase 2 Celia study of diranersen, an antisense oligonucleotide that blocks the production of tau by binding to its precursor mRNA. Tau is one of two proteins that become deformed and clumped in Alzheimer’s, with the other, amyloid beta, already successfully targeted by Biogen’s Leqembi and Eli Lilly’s Kisunla.
